modelLevonorgestrelAndEstroge
Extends from Pharmacolibrary.Drugs.ATC.G.G03FB09.
Information
| name: | LevonorgestrelAndEstrogen | |
| ATC code: | G03FB09 | route: | oral |
| compartments: | 1 | |
| dosage: | 0.15 | mg |
| volume of distribution: | 1.3 | L |
| clearance: | 1.0 | L/h/kg |
| other parameters in model implementation | ||
Levonorgestrel and estrogen are used in combination as oral contraceptives for the prevention of pregnancy. The combination is widely used and approved for contraceptive purposes in many countries. Levonorgestrel is a synthetic progestogen, while estrogen (usually ethinylestradiol) is a synthetic estrogen component.
Pharmacokinetics
Pharmacokinetic parameters are estimated for a typical healthy adult non-pregnant female, population for oral combined hormonal contraceptive use. No direct reference describing full compartmental PK parameters for the specific combination with ATC code G03FB09 was found.
References
Adedoyin, A, et al., & Iwamoto, M (2019). Effect of letermovir on levonorgestrel and ethinyl estradiol pharmacokinetics . International journal of clinical pharmacology and therapeutics 57(9) 450–457. DOI:10.5414/CP203483 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31232280
Kanarkowski, R, et al., & Jusko, WJ (1988). Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. Clinical pharmacology and therapeutics 43(1) 23–31. DOI:10.1038/clpt.1988.7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/3121231
Kuhnz, W (1990). Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women. American journal of obstetrics and gynecology 163(6 Pt 2) 2120–2127. DOI:10.1016/0002-9378(90)90551-h PUBMED:https://pubmed.ncbi.nlm.nih.gov/2124087
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)